Cookie Law

På vår hemsida används cookies, varav några är väsentliga för att denna webbplats ska fungera korrekt och redan ha ställts in. För mer information om hantering, blockering eller radering av cookies i din webbläsare, se hänvisningarna i vår sekretesspolicy. Genom att använda vår webbplats accepterar du villkoren i vår sekretesspolicy.

Functional Cookies

Functional cookies are essential to make the website work properly. These cookies do not collect any personal data.

View details

Website Statistics

Allow us to collect anonymous statistics about how the website is used. The data collected in this manner is aggregated for the purpose of analysing usage trends on the website.

View details

Youtube/Vimeo videos

Videos on this website are provided by the YouTube streaming media platform. YouTube can display personalized ads prior to the video showing. This permission is optional, but necessary to view videos directly on this website.

View details

Glöm mina inställningar Deleted!

Summary of Indications for Use
DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE SJ (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure. There are no known contraindications

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. .

Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling (1mL / 3mL).

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

© 2019 Bioventus LLC.

^{*First introduced in the European Union in 2001.}

To learn more about DUROLANE or for contact information, please select your location to continue.

Osteoarthritis: The Ongoing Challenges to Manage Pain

Choroba zwyrodnieniowa stawów: bieżące wyzwania w zakresie radzenia sobie z bólem

[youtube_blok]https://youtu.be/m8AXUq5uA0Y[/youtube_blok]

[vimeo_blok]https://vimeo.com/281282602[/vimeo_blok]

[youtube_blok] src=https://www.youtube.com/embed/TueE6NWHtVs width=560 height=315 [/youtube_blok]